SCHEMBL23489012

SCHEMBL23489012

C#CC(=O)OC(=O)c1cc(OC)c(OC)c(OC)c1N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.66
POLB P06746 2/20 0.66
USP2 O75604 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.40
TUBB4A P04350 3/20 0.36
TUBB P07437 3/20 0.36
TUBA3C P0DPH7 3/20 0.36
TUBA1B P68363 3/20 0.36
TUBA4A P68366 3/20 0.36
TUBB4B P68371 3/20 0.36
TUBB3 Q13509 3/20 0.36
TUBB2A Q13885 3/20 0.36
TUBB8 Q3ZCM7 3/20 0.36
TUBA3E Q6PEY2 3/20 0.36
TUBA1A Q71U36 3/20 0.36
TUBA1C Q9BQE3 3/20 0.36
TUBB6 Q9BUF5 3/20 0.36
TUBB2B Q9BVA1 3/20 0.36
TUBB1 Q9H4B7 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25039183 0.82 KDM4E (0.64) KDM4EPOLBUSP2HSD17B10PKM
SCHEMBL25037578 0.81 KDM4E (0.63) KDM4EPOLBHSD17B10ALDH1A1HPGD
SCHEMBL4734795 0.80 KDM4E (1.00) KDM4EPOLBUSP2HSD17B10PKM
SCHEMBL30498915 0.75 KDM4E (0.72) KDM4EPOLBUSP2HSD17B10PKM
SCHEMBL2034454 0.75 KDM4E (0.72) KDM4EPOLBUSP2HSD17B10PKM
SCHEMBL28594907 0.75 KDM4E (0.72) KDM4EPOLBUSP2HSD17B10PKM
SCHEMBL23489021 0.71 KDM4E (0.50) KDM4EHSD17B10SMN1; SMN2TSHRALDH1A1
SCHEMBL20600282 0.71 KDM4E (0.57) KDM4EPOLBUSP2HSD17B10PKM
SCHEMBL28944983 0.71 KDM4E (0.53) KDM4EPOLBHSD17B10PKMALDH1A1
SCHEMBL28329924 0.70 KDM4E (0.64) KDM4EPOLBUSP2HSD17B10PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605353-B2 PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes ACADEMIA SINICA (TW) 2026-04-21 US disclosed
US-20230046445-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES ACADEMIA SINICA (TW) 2023-02-16 US disclosed
US-20230046445-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES ACADEMIA SINICA (TW) 2023-02-16 US disclosed
CN-114761025-A PDIA4 inhibitor and application thereof in inhibiting beta cell pathology and treating diabetes 施明哲 2022-07-15 CN disclosed
WO-2021113062-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES ACADEMIA SINICA (CN) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605353-B2 PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes PDIA4, PDIA5, PDIA6 KDM4E 2024/4885POLB 4409/4885USP2 1555/4885
US-20230046445-A1 PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES PDIA4, PDIA6, PDIA5 KDM4E 1437/4885POLB 4041/4885USP2 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.